For comments, suggestions
Created with Raphaël 2.1.0 13.04.2016 Filing date 14.11.2017 Validation fee payment 30.04.2018 (A1) Patent application published 23.03.2020 AGEPI application filing date 31.05.2020 (T2) Translation of the validated European patent 04.05.2025 13.04.2026 Valid until 14.04.2027 Renewal fee to be paid until 13.04.2036 Patent will expire on

Patent in force


(210)Number of the EPO application16779363
(220)Filing date of the EPO application2016.04.13
(80)EPO patent specification publication (B)EPB nr. 01/2020, 2020.01.01
(110)EPO patent number3283067
(11)Number of the documentMD 3283067 T2
(21)Number of the applicatione 2018 0191
(71)Name(s) of applicant(s), code of the countryMilestone Pharmaceuticals Inc., CA;
(72)Name(s) of inventor(s), code of the countryMAGUIRE Martin P., US;
(73)Name(s) of owner(s), code of the countryMILESTONE Pharmaceuticals Inc., CA;
(54)Title of the inventionHighly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
(13)Kind-of-document code T2
(51)International Patent Classification A61K 31/277 (2006.01.01); A61K 9/08 (2006.01.01); A61K 9/00 (2006.01.01); A61P 25/06 (2006.01.01); A61P 9/00 (2006.01.01); A61P 9/06 (2006.01.01); A61P 9/10 (2006.01.01); C07C 255/42 (2006.01.01); A61K 47/20 (2006.01.01); A61K 47/18 (2017.01.01); A61K 47/12 (2006.01.01)
(19)CountryCA
(41)Date of publication of the application2018.04.30
(49)Date of publication of the translation of the validated European patent specification2020.05.31
(30)Priority201562147427 P, 2015.04.14, US
(74)Patent attorney(Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova
(86)International applicationPCT/CA2016/050425, 2016.04.13
(87)International publicationWO 2016/165014, 2016.10.20
Up
/Inventions/details/3283067